CL2020000120A1 - Composiciones farmacéuticas. - Google Patents

Composiciones farmacéuticas.

Info

Publication number
CL2020000120A1
CL2020000120A1 CL2020000120A CL2020000120A CL2020000120A1 CL 2020000120 A1 CL2020000120 A1 CL 2020000120A1 CL 2020000120 A CL2020000120 A CL 2020000120A CL 2020000120 A CL2020000120 A CL 2020000120A CL 2020000120 A1 CL2020000120 A1 CL 2020000120A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
trfatermin
composedition
valsartan
atorvastatin
Prior art date
Application number
CL2020000120A
Other languages
English (en)
Inventor
Matthew Carl Allgeier
Tony Yantao Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020000120A1 publication Critical patent/CL2020000120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES SÓLIDAS DE DOSIS FIJA ORAL DE METFORMINA, ATORVASTATINA Y VALSARTÁN, O SALES ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO DE ESTOS, PROCESOS PARA LA PREPARACIÓN DE ESTAS Y EL USO DE LA COMPOSICIÓN PARA TRATAR CIERTAS ENFERMEDADES.
CL2020000120A 2017-07-17 2020-01-15 Composiciones farmacéuticas. CL2020000120A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533332P 2017-07-17 2017-07-17
US201762538936P 2017-07-31 2017-07-31

Publications (1)

Publication Number Publication Date
CL2020000120A1 true CL2020000120A1 (es) 2020-07-17

Family

ID=63036446

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000120A CL2020000120A1 (es) 2017-07-17 2020-01-15 Composiciones farmacéuticas.

Country Status (24)

Country Link
US (2) US11376223B2 (es)
EP (1) EP3654955A1 (es)
JP (1) JP6854384B2 (es)
KR (1) KR102409102B1 (es)
CN (1) CN110913843B (es)
AU (1) AU2018301924B2 (es)
BR (1) BR112019028278A2 (es)
CA (1) CA3069948C (es)
CL (1) CL2020000120A1 (es)
CO (1) CO2019015099A2 (es)
CR (1) CR20190577A (es)
DO (1) DOP2020000010A (es)
EC (1) ECSP20003493A (es)
IL (1) IL272044A (es)
JO (1) JOP20200005A1 (es)
MA (1) MA49625A (es)
MY (1) MY198062A (es)
PE (1) PE20200174A1 (es)
PH (1) PH12020500120A1 (es)
SA (1) SA520410976B1 (es)
SG (1) SG11201912482WA (es)
UA (1) UA125535C2 (es)
WO (1) WO2019018155A1 (es)
ZA (1) ZA201908550B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102409102B1 (ko) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 제약 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN1688341A (zh) * 2002-08-08 2005-10-26 三共株式会社 降低血脂的药物组合物
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
SI2120878T1 (sl) 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
MX2013000824A (es) 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US9572784B2 (en) * 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
HUE030674T2 (en) * 2012-03-30 2017-06-28 Dae Woong Pharma A pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR102013028883A2 (pt) 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
WO2016040462A2 (en) 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
KR102409102B1 (ko) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 제약 조성물

Also Published As

Publication number Publication date
NZ760868A (en) 2023-09-29
US11376223B2 (en) 2022-07-05
ECSP20003493A (es) 2020-08-31
CO2019015099A2 (es) 2020-01-17
JP2020527147A (ja) 2020-09-03
PE20200174A1 (es) 2020-01-24
US20220287978A1 (en) 2022-09-15
KR20200015758A (ko) 2020-02-12
MY198062A (en) 2023-07-31
US11918692B2 (en) 2024-03-05
JP6854384B2 (ja) 2021-04-07
CA3069948C (en) 2022-05-17
AU2018301924B2 (en) 2021-07-29
ZA201908550B (en) 2024-06-26
EP3654955A1 (en) 2020-05-27
MA49625A (fr) 2020-05-27
CA3069948A1 (en) 2019-01-24
CR20190577A (es) 2020-01-29
CN110913843B (zh) 2022-09-13
KR102409102B1 (ko) 2022-06-16
JOP20200005A1 (ar) 2020-01-14
DOP2020000010A (es) 2020-02-28
UA125535C2 (uk) 2022-04-13
PH12020500120A1 (en) 2020-09-28
SG11201912482WA (en) 2020-02-27
WO2019018155A1 (en) 2019-01-24
CN110913843A (zh) 2020-03-24
SA520410976B1 (ar) 2023-03-23
IL272044A (en) 2020-03-31
US20210137842A1 (en) 2021-05-13
AU2018301924A1 (en) 2019-12-19
BR112019028278A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2016002970A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo.
SV2018005778A (es) Derivados aromaticos de sulfonamida
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
DOP2015000274A (es) Compuestos químicos
CR20170315A (es) Inhibridores bace 1 selectivos
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
BR112017028140A2 (pt) formulações farmacêuticas
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EA201692298A1 (ru) Производные карбоксамидов
UY36124A (es) Derivados de carboxamida
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
CR20180089A (es) Compuestos útiles para inhibir a ror-gamma-t
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
IL283105A (en) Combination of MCL-1 inhibitor and midostearoin, its uses and pharmaceutical preparations
CL2020000120A1 (es) Composiciones farmacéuticas.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
BR112019001024A2 (pt) combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas
EA201890477A1 (ru) Инкапсулированная композиция финголимода
WO2016020408A3 (en) Compounds for preventing ototoxicity